PepGen Inc.
Last updated September 27, 2026
Organization details
- Legal name
- PepGen Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PEPG
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001835597
Board of directors
-
Christopher Ashton · DirectorSince 2023
- Since 2023
-
Heidi Henson · DirectorSince 2023
-
Howard Mayer · DirectorSince 2023
-
James G. McArthur · Director · President and CEOSince 2023
-
Joshua Resnick · DirectorSince 2023
-
Laurie Keating · DirectorSince 2023
-
Lisa Wyman · DirectorSince 2025
-
Mitchell H. Finer · DirectorSince 2025
- Since 2024
- Since 2024
Chief executives
James G. McArthur
· President and CEO
Dates unknown
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.2%
-
80.9%
-
88.4%
Board connections
6 of this board's directors also sit on 31 other boards. 31 are in the same sector.
-
Jade Biosciences Inc. Same sectorvia Habib J. Dable, Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
Vor Biopharma Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Immuneering Corporation Same sectorvia Laurie Keating
-
Kalaris Therapeutics Inc. Same sectorvia Laurie Keating
-
Korsana Biosciences Inc. Same sectorvia Heidi Henson
-
Lisata Therapeutics Inc. Same sectorvia Heidi Henson
-
Perspective Therapeutics Inc. Same sectorvia Heidi Henson
-
Relay Therapeutics Inc. Same sectorvia Habib J. Dable
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $59,312
- 7 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 21, 2026 | Kasraian Kasra Officer (Chief Technical Officer) | Open-market sale | −1,233 | $1.41 | $1,739 |
| Mar 4, 2026 | STRECK PAUL Officer (EVP, Head of R&D) | Open-market sale | −1,832 | $6.23 | $11,413 |
| Mar 4, 2026 | Donnelly Noel Officer (Chief Financial Officer) | Open-market sale | −2,032 | $6.23 | $12,659 |
| Mar 4, 2026 | James G. McArthur Director, Officer (President and CEO) | Open-market sale | −5,144 | $6.23 | $32,047 |
| Mar 4, 2026 | STRECK PAUL Officer (EVP, Head of R&D) | Open-market sale | −47 | $6.29 | $296 |
| Mar 4, 2026 | Donnelly Noel Officer (Chief Financial Officer) | Open-market sale | −52 | $6.33 | $329 |
| Mar 4, 2026 | James G. McArthur Director, Officer (President and CEO) | Open-market sale | −131 | $6.33 | $829 |
| Mar 1, 2026 | Vittiglio Joseph Officer (Chief Business & Legal Officer) | Grant or award | +30,717 | — | — |
| Mar 1, 2026 | Kasraian Kasra Officer (Chief Technical Officer) | Grant or award | +34,557 | — | — |
| Mar 1, 2026 | STRECK PAUL Officer (EVP, Head of R&D) | Grant or award | +50,300 | — | — |
| Mar 1, 2026 | Donnelly Noel Officer (Chief Financial Officer) | Grant or award | +76,793 | — | — |
| Mar 1, 2026 | James G. McArthur Director, Officer (President and CEO) | Grant or award | +187,688 | — | — |
| Dec 8, 2025 | Vittiglio Joseph Officer (Chief Business & Legal Officer) | Grant or award | +35,000 | — | — |
| Sep 30, 2025 | Oxford Science Enterprises plc Former 10% Owner | Open-market purchase | +200,000 | $3.20 | $640,000 |
| Sep 26, 2025 | RA Capital Healthcare Fund LP Director, 10% owner | Open-market purchase | +9,375,000 | $3.20 | $30,000,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about PepGen Inc.
Who is the CEO of PepGen Inc.?
James G. McArthur is PepGen Inc.'s President and CEO.
How many directors are on PepGen Inc.'s board?
PepGen Inc.'s board has 11 directors: Christopher Ashton, Habib J. Dable, Heidi Henson, Howard Mayer, James G. McArthur, Joshua Resnick, Laurie Keating, Lisa Wyman, Mitchell H. Finer, Peter Kolchinsky and 1 other.
Are PepGen Inc. insiders buying or selling shares?
Over the last 12 months, PepGen Inc. insiders made no open-market purchases and sold $59,312 of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="pepgen-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.